Co-Author
This page shows the publications co-authored by Jack Bergman and Brian Kangas.
Connection Strength
7.088
-
Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates. J Pharmacol Exp Ther. 2020 01; 372(1):119-127.
Score: 0.840
-
Touchscreen technology in the study of cognition-related behavior. Behav Pharmacol. 2017 12; 28(8):623-629.
Score: 0.737
-
Effects of self-administered methamphetamine on discrimination learning and reversal in nonhuman primates. Psychopharmacology (Berl). 2016 Feb; 233(3):373-80.
Score: 0.649
-
Comparisons of ?9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates. J Pharmacol Exp Ther. 2016 Apr; 357(1):125-33.
Score: 0.649
-
Operant nociception in nonhuman primates. Pain. 2014 Sep; 155(9):1821-1828.
Score: 0.581
-
Repeated acquisition and discrimination reversal in the squirrel monkey (Saimiri sciureus). Anim Cogn. 2014 Mar; 17(2):221-8.
Score: 0.542
-
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther. 2013 Mar; 344(3):561-7.
Score: 0.525
-
A novel touch-sensitive apparatus for behavioral studies in unrestrained squirrel monkeys. J Neurosci Methods. 2012 Aug 15; 209(2):331-6.
Score: 0.507
-
Concurrent electrophysiological recording and cognitive testing in a rodent touchscreen environment. Sci Rep. 2021 06 03; 11(1):11665.
Score: 0.235
-
Translational Assessments of Reward Responsiveness in the Marmoset. Int J Neuropsychopharmacol. 2021 05 18; 24(5):409-418.
Score: 0.234
-
Empirical validation of a touchscreen probabilistic reward task in rats. Transl Psychiatry. 2020 08 13; 10(1):285.
Score: 0.222
-
Antiemetic Effects of Cannabinoid Agonists in Nonhuman Primates. J Pharmacol Exp Ther. 2020 09; 374(3):462-468.
Score: 0.220
-
Discrimination learning in oxycodone-treated nonhuman primates. Drug Alcohol Depend. 2020 02 01; 207:107778.
Score: 0.212
-
Effects of chronic cocaine self-administration and N-acetylcysteine on learning, cognitive flexibility, and reinstatement in nonhuman primates. Psychopharmacology (Berl). 2019 Jul; 236(7):2143-2153.
Score: 0.201
-
Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors. J Pharmacol Exp Ther. 2017 12; 363(3):314-323.
Score: 0.182
-
Touchscreen assays of learning, response inhibition, and motivation in the marmoset (Callithrix jacchus). Anim Cogn. 2016 May; 19(3):673-7.
Score: 0.162
-
Error-related Alpha Suppression: Scalp Topography and (Lack of) Modulation by Modafinil. J Cogn Neurosci. 2022 Mar 31; 34(5):864-876.
Score: 0.062
-
Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders. Biomedicines. 2022 Feb 07; 10(2).
Score: 0.062
-
Concordant neurophysiological signatures of cognitive control in humans and rats. Neuropsychopharmacology. 2021 06; 46(7):1252-1262.
Score: 0.058
-
Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition. J Pharmacol Exp Ther. 2021 06; 377(3):336-345.
Score: 0.058
-
Effects of daily ?9-Tetrahydrocannabinol (THC) alone or combined with cannabidiol (CBD) on cognition-based behavior and activity in adolescent nonhuman primates. Drug Alcohol Depend. 2021 04 01; 221:108629.
Score: 0.058
-
Effects of long-term cocaine self-administration on brain resting-state functional connectivity in nonhuman primates. Transl Psychiatry. 2020 12 02; 10(1):420.
Score: 0.057
-
Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat Neurosci. 2013 Nov; 16(11):1652-61.
Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.